Advanced oncology treatment for HR-positive, HER2-negative metastatic breast cancer.
Active Ingredient: Palbociclib Breast cancer, advanced (initial endocrine-based therapy): Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor) in postmenopausal women as initial endocrine-based therapy
Breast cancer, advanced (with disease progression following endocrine therapy): Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer (in combination with fulvestrant) in women with disease progression following endocrine therapy